MedTrace Logo

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

NCT02632175 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-10-16

Study results available
· View outcomes & findings →

Summary

This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.

Conditions

Interventions

BIOLOGICAL

Adalimumab

every other week or weekly subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-26
Primary Completion
2025-04-08
Completion
2025-04-08
FDA Drug
Yes

Countries

  • United States
  • Japan
  • Poland
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02632175 on ClinicalTrials.gov